Physician profile
David Jay Baggett
NPI 1598838229
$12,226.60
in general payments reported to CMS, 2019-2025
65 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,092 · 2020: $1,526 · 2021: $1,995 · 2022: $1,935 · 2023: $1,944 · 2024: $1,482 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,673 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,673.01 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,198.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,049.64 | 2019-2025 | Vraylar, Linzess, Qulipta |
| Amgen INC. | $1,008.96 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $746.45 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $736.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $652.64 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $608.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.80 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Antares Pharma, INC. | $385.13 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Amarin Pharma, INC. | $364.07 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $350.51 | 2019-2024 | Qelbree, Qelbree, Xyosted |
| Astellas Pharma US INC | $309.86 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $290.69 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $253.84 | 2020-2023 | Verquvo, Belsomra |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baggett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.